Effect  ||| S:0 E:7 ||| NN
of  ||| S:7 E:10 ||| IN
benazepril  ||| S:10 E:21 ||| NN
on  ||| S:21 E:24 ||| IN
cardiac  ||| S:24 E:32 ||| JJ
function  ||| S:32 E:41 ||| NN
in  ||| S:41 E:44 ||| IN
Chinese  ||| S:44 E:52 ||| JJ
patients  ||| S:52 E:61 ||| NNS
with  ||| S:61 E:66 ||| IN
chronic  ||| S:66 E:74 ||| JJ
heart  ||| S:74 E:80 ||| NN
failure ||| S:80 E:87 ||| NN
:  ||| S:87 E:89 ||| :
a  ||| S:89 E:91 ||| DT
meta-analysis  ||| S:91 E:105 ||| JJ
of  ||| S:105 E:108 ||| IN
randomized  ||| S:108 E:119 ||| JJ
controlled  ||| S:119 E:130 ||| JJ
trials  ||| S:130 E:137 ||| NNS
To  ||| S:137 E:140 ||| TO
evaluate  ||| S:140 E:149 ||| VB
the  ||| S:149 E:153 ||| DT
efficacy  ||| S:153 E:162 ||| NN
and  ||| S:162 E:166 ||| CC
tolerability  ||| S:166 E:179 ||| NN
of  ||| S:179 E:182 ||| IN
benazepril  ||| S:182 E:193 ||| NN
in  ||| S:193 E:196 ||| IN
Chinese  ||| S:196 E:204 ||| JJ
patients  ||| S:204 E:213 ||| NNS
with  ||| S:213 E:218 ||| IN
chronic  ||| S:218 E:226 ||| JJ
systolic  ||| S:226 E:235 ||| JJ
heart  ||| S:235 E:241 ||| NN
failure ||| S:241 E:248 ||| NN
.  ||| S:248 E:250 ||| .
We  ||| S:250 E:253 ||| PRP
searched  ||| S:253 E:262 ||| VBD
the  ||| S:262 E:266 ||| DT
databases  ||| S:266 E:276 ||| NN
of  ||| S:276 E:279 ||| IN
Cochrane ||| S:279 E:287 ||| NNP
,  ||| S:287 E:289 ||| ,
PubMed ||| S:289 E:295 ||| NNP
,  ||| S:295 E:297 ||| ,
EMbase ||| S:297 E:303 ||| NNP
,  ||| S:303 E:305 ||| ,
CBM  ||| S:305 E:309 ||| NNP
and  ||| S:309 E:313 ||| CC
CNKI  ||| S:313 E:318 ||| NNP
from  ||| S:318 E:323 ||| IN
January  ||| S:323 E:331 ||| NNP
1989  ||| S:331 E:336 ||| CD
to  ||| S:336 E:339 ||| TO
November  ||| S:339 E:348 ||| NNP
2010  ||| S:348 E:353 ||| CD
for  ||| S:353 E:357 ||| IN
the  ||| S:357 E:361 ||| DT
relevant  ||| S:361 E:370 ||| JJ
studies ||| S:370 E:377 ||| NNS
.  ||| S:377 E:379 ||| .
Two  ||| S:379 E:383 ||| CD
investigators  ||| S:383 E:397 ||| NNS
identified  ||| S:397 E:408 ||| VBD
randomized  ||| S:408 E:419 ||| VBN
controlled  ||| S:419 E:430 ||| VBN
trials  ||| S:430 E:437 ||| NNS
( ||| S:437 E:438 ||| -LRB-
RCTs ||| S:438 E:442 ||| NNP
)  ||| S:442 E:444 ||| -RRB-
independently  ||| S:444 E:458 ||| RB
according  ||| S:458 E:468 ||| VBG
to  ||| S:468 E:471 ||| TO
the  ||| S:471 E:475 ||| DT
predefined  ||| S:475 E:486 ||| JJ
inclusion  ||| S:486 E:496 ||| NN
and  ||| S:496 E:500 ||| CC
exclusion  ||| S:500 E:510 ||| NN
criteria ||| S:510 E:518 ||| NNS
.  ||| S:518 E:520 ||| .
Statistical  ||| S:520 E:532 ||| JJ
data  ||| S:532 E:537 ||| NN
analysis  ||| S:537 E:546 ||| NN
was  ||| S:546 E:550 ||| VBD
performed  ||| S:550 E:560 ||| VBN
with  ||| S:560 E:565 ||| IN
the  ||| S:565 E:569 ||| DT
Stata  ||| S:569 E:575 ||| NNP
11  ||| S:575 E:578 ||| CD
software ||| S:578 E:586 ||| NN
.  ||| S:586 E:588 ||| .
A  ||| S:588 E:590 ||| DT
total  ||| S:590 E:596 ||| NN
of  ||| S:596 E:599 ||| IN
15  ||| S:599 E:602 ||| CD
studies  ||| S:602 E:610 ||| NNS
with  ||| S:610 E:615 ||| IN
1  ||| S:615 E:617 ||| CD
355  ||| S:617 E:621 ||| CD
Chinese  ||| S:621 E:629 ||| JJ
patients  ||| S:629 E:638 ||| NNS
of  ||| S:638 E:641 ||| IN
chronic  ||| S:641 E:649 ||| JJ
systolic  ||| S:649 E:658 ||| JJ
heart  ||| S:658 E:664 ||| NN
failure  ||| S:664 E:672 ||| NN
fulfilled  ||| S:672 E:682 ||| VBD
the  ||| S:682 E:686 ||| DT
inclusion  ||| S:686 E:696 ||| NN
criteria ||| S:696 E:704 ||| NNS
.  ||| S:704 E:706 ||| .
Among  ||| S:706 E:712 ||| IN
them ||| S:712 E:716 ||| PRP
,  ||| S:716 E:718 ||| ,
546  ||| S:718 E:722 ||| CD
received  ||| S:722 E:731 ||| VBD
benazepril  ||| S:731 E:742 ||| JJ
monotherapy ||| S:742 E:753 ||| NN
.  ||| S:753 E:755 ||| .
The  ||| S:755 E:759 ||| DT
dose  ||| S:759 E:764 ||| NN
range  ||| S:764 E:770 ||| NN
of  ||| S:770 E:773 ||| IN
benazepril  ||| S:773 E:784 ||| NN
was  ||| S:784 E:788 ||| VBD
5  ||| S:788 E:790 ||| CD
to  ||| S:790 E:793 ||| TO
40  ||| S:793 E:796 ||| CD
mg  ||| S:796 E:799 ||| CD
daily ||| S:799 E:804 ||| JJ
.  ||| S:804 E:806 ||| .
And  ||| S:806 E:810 ||| CC
it  ||| S:810 E:813 ||| PRP
was  ||| S:813 E:817 ||| VBD
similar  ||| S:817 E:825 ||| JJ
to  ||| S:825 E:828 ||| TO
angiotensin  ||| S:828 E:840 ||| VB
II  ||| S:840 E:843 ||| NNP
receptor  ||| S:843 E:852 ||| FW
blockers  ||| S:852 E:861 ||| FW
( ||| S:861 E:862 ||| -LRB-
ARBs ||| S:862 E:866 ||| NNP
)  ||| S:866 E:868 ||| -RRB-
in  ||| S:868 E:871 ||| IN
improving  ||| S:871 E:881 ||| VBG
left  ||| S:881 E:886 ||| VBN
ventricular  ||| S:886 E:898 ||| JJ
ejection  ||| S:898 E:907 ||| JJ
fraction  ||| S:907 E:916 ||| NN
( ||| S:916 E:917 ||| -LRB-
LVEF ||| S:917 E:921 ||| NNP
) ||| S:921 E:922 ||| -RRB-
( ||| S:922 E:923 ||| -LRB-
P  ||| S:923 E:925 ||| NN
=  ||| S:925 E:927 ||| SYM
0.674 ||| S:927 E:932 ||| CD
) ||| S:932 E:933 ||| -RRB-
,  ||| S:933 E:935 ||| ,
reducing  ||| S:935 E:944 ||| VBG
LVEDD  ||| S:944 E:950 ||| NNP
( ||| S:950 E:951 ||| -LRB-
P  ||| S:951 E:953 ||| NN
=  ||| S:953 E:955 ||| SYM
0.511 ||| S:955 E:960 ||| CD
)  ||| S:960 E:962 ||| -RRB-
and  ||| S:962 E:966 ||| CC
improving  ||| S:966 E:976 ||| VBG
cardiac  ||| S:976 E:984 ||| JJ
output  ||| S:984 E:991 ||| NN
( ||| S:991 E:992 ||| -LRB-
P  ||| S:992 E:994 ||| NN
=  ||| S:994 E:996 ||| SYM
0.363 ||| S:996 E:1001 ||| CD
) ||| S:1001 E:1002 ||| -RRB-
.  ||| S:1002 E:1004 ||| .
The  ||| S:1004 E:1008 ||| DT
combination  ||| S:1008 E:1020 ||| NN
therapy  ||| S:1020 E:1028 ||| NN
of  ||| S:1028 E:1031 ||| IN
benazepril  ||| S:1031 E:1042 ||| NN
and  ||| S:1042 E:1046 ||| CC
ARB  ||| S:1046 E:1050 ||| NNP
was  ||| S:1050 E:1054 ||| VBD
superior  ||| S:1054 E:1063 ||| JJ
to  ||| S:1063 E:1066 ||| TO
ARB  ||| S:1066 E:1070 ||| NNP
monotherapy  ||| S:1070 E:1082 ||| NN
in  ||| S:1082 E:1085 ||| IN
reducing  ||| S:1085 E:1094 ||| VBG
left  ||| S:1094 E:1099 ||| VBN
ventricular  ||| S:1099 E:1111 ||| JJ
end-diastolic  ||| S:1111 E:1125 ||| JJ
diameter  ||| S:1125 E:1134 ||| NNS
( ||| S:1134 E:1135 ||| -LRB-
LVEDD ||| S:1135 E:1140 ||| NNP
)  ||| S:1140 E:1142 ||| -RRB-
( ||| S:1142 E:1143 ||| -LRB-
P  ||| S:1143 E:1145 ||| NN
=  ||| S:1145 E:1147 ||| SYM
0.001 ||| S:1147 E:1152 ||| CD
) ||| S:1152 E:1153 ||| -RRB-
.  ||| S:1153 E:1155 ||| .
However ||| S:1155 E:1162 ||| RB
,  ||| S:1162 E:1164 ||| ,
LVEF  ||| S:1164 E:1169 ||| NNP
was  ||| S:1169 E:1173 ||| VBD
comparable  ||| S:1173 E:1184 ||| JJ
between  ||| S:1184 E:1192 ||| IN
patients  ||| S:1192 E:1201 ||| NNS
with  ||| S:1201 E:1206 ||| IN
ACEI ||| S:1206 E:1210 ||| NNP
/ ||| S:1210 E:1211 ||| NNP
ARB  ||| S:1211 E:1215 ||| NNP
combination  ||| S:1215 E:1227 ||| NN
therapy  ||| S:1227 E:1235 ||| NN
and  ||| S:1235 E:1239 ||| CC
those  ||| S:1239 E:1245 ||| DT
with  ||| S:1245 E:1250 ||| IN
ARB  ||| S:1250 E:1254 ||| NNP
monotherapy  ||| S:1254 E:1266 ||| NNS
( ||| S:1266 E:1267 ||| -LRB-
P  ||| S:1267 E:1269 ||| NN
=  ||| S:1269 E:1271 ||| SYM
0.105 ||| S:1271 E:1276 ||| CD
) ||| S:1276 E:1277 ||| -RRB-
.  ||| S:1277 E:1279 ||| .
Compared  ||| S:1279 E:1288 ||| VBN
with  ||| S:1288 E:1293 ||| IN
blank  ||| S:1293 E:1299 ||| JJ
control ||| S:1299 E:1306 ||| NN
,  ||| S:1306 E:1308 ||| ,
benazepril  ||| S:1308 E:1319 ||| JJ
treatment  ||| S:1319 E:1329 ||| NN
was  ||| S:1329 E:1333 ||| VBD
associated  ||| S:1333 E:1344 ||| VBN
with  ||| S:1344 E:1349 ||| IN
a  ||| S:1349 E:1351 ||| DT
significant  ||| S:1351 E:1363 ||| JJ
improvement  ||| S:1363 E:1375 ||| NN
in  ||| S:1375 E:1378 ||| IN
LVEF  ||| S:1378 E:1383 ||| NNP
from  ||| S:1383 E:1388 ||| IN
baseline  ||| S:1388 E:1397 ||| NN
to  ||| S:1397 E:1400 ||| TO
follow-up  ||| S:1400 E:1410 ||| NNP
( ||| S:1410 E:1411 ||| -LRB-
WMD  ||| S:1411 E:1415 ||| NNP
=  ||| S:1415 E:1417 ||| SYM
6.5 ||| S:1417 E:1420 ||| CD
% ||| S:1420 E:1421 ||| NN
;  ||| S:1421 E:1423 ||| :
95 ||| S:1423 E:1425 ||| CD
%  ||| S:1425 E:1427 ||| NN
CI ||| S:1427 E:1429 ||| NNP
:  ||| S:1429 E:1431 ||| :
0.9 ||| S:1431 E:1434 ||| CD
% ||| S:1434 E:1435 ||| NN
,  ||| S:1435 E:1437 ||| ,
12.0 ||| S:1437 E:1441 ||| CD
% ||| S:1441 E:1442 ||| NN
;  ||| S:1442 E:1444 ||| :
P  ||| S:1444 E:1446 ||| NN
=  ||| S:1446 E:1448 ||| SYM
0.022 ||| S:1448 E:1453 ||| CD
) ||| S:1453 E:1454 ||| -RRB-
.  ||| S:1454 E:1456 ||| .
Compared  ||| S:1456 E:1465 ||| VBN
with  ||| S:1465 E:1470 ||| IN
baseline ||| S:1470 E:1478 ||| NN
,  ||| S:1478 E:1480 ||| ,
benazepril  ||| S:1480 E:1491 ||| JJ
treatment  ||| S:1491 E:1501 ||| NN
significantly  ||| S:1501 E:1515 ||| RB
increased  ||| S:1515 E:1525 ||| VBN
LVEF  ||| S:1525 E:1530 ||| NNP
( ||| S:1530 E:1531 ||| -LRB-
WMD  ||| S:1531 E:1535 ||| NNP
=  ||| S:1535 E:1537 ||| SYM
10.4 ||| S:1537 E:1541 ||| CD
% ||| S:1541 E:1542 ||| NN
;  ||| S:1542 E:1544 ||| :
95 ||| S:1544 E:1546 ||| CD
%  ||| S:1546 E:1548 ||| NN
confidence  ||| S:1548 E:1559 ||| NN
interval  ||| S:1559 E:1568 ||| NNS
[ ||| S:1568 E:1569 ||| -LRB-
CI ||| S:1569 E:1571 ||| NNP
] ||| S:1571 E:1572 ||| -RRB-
: ||| S:1572 E:1573 ||| :
7.1 ||| S:1573 E:1576 ||| CD
% ||| S:1576 E:1577 ||| NN
,  ||| S:1577 E:1579 ||| ,
13.8 ||| S:1579 E:1583 ||| CD
% ||| S:1583 E:1584 ||| NN
;  ||| S:1584 E:1586 ||| :
P  ||| S:1586 E:1588 ||| NNP
< ||| S:1588 E:1590 ||| SYM
0.001 ||| S:1590 E:1595 ||| NNP
)  ||| S:1595 E:1597 ||| -RRB-
and  ||| S:1597 E:1601 ||| CC
cardiac  ||| S:1601 E:1609 ||| JJ
output  ||| S:1609 E:1616 ||| NN
( ||| S:1616 E:1617 ||| -LRB-
WMD  ||| S:1617 E:1621 ||| NNP
=  ||| S:1621 E:1623 ||| SYM
1.5  ||| S:1623 E:1627 ||| CD
L ||| S:1627 E:1628 ||| NNP
;  ||| S:1628 E:1630 ||| :
CI ||| S:1630 E:1632 ||| NNP
: ||| S:1632 E:1633 ||| :
0.3 ||| S:1633 E:1636 ||| CD
,  ||| S:1636 E:1638 ||| ,
2.6  ||| S:1638 E:1642 ||| CD
L ||| S:1642 E:1643 ||| NNP
,  ||| S:1643 E:1645 ||| ,
P  ||| S:1645 E:1647 ||| NN
=  ||| S:1647 E:1649 ||| SYM
0.016 ||| S:1649 E:1654 ||| CD
) ||| S:1654 E:1655 ||| -RRB-
.  ||| S:1655 E:1657 ||| .
A  ||| S:1657 E:1659 ||| DT
significant  ||| S:1659 E:1671 ||| JJ
reduction  ||| S:1671 E:1681 ||| NN
in  ||| S:1681 E:1684 ||| IN
LVEDD  ||| S:1684 E:1690 ||| NNP
( ||| S:1690 E:1691 ||| -LRB-
WMD  ||| S:1691 E:1695 ||| NNP
=  ||| S:1695 E:1697 ||| SYM
5.3  ||| S:1697 E:1701 ||| CD
mm ||| S:1701 E:1703 ||| NNS
;  ||| S:1703 E:1705 ||| :
CI ||| S:1705 E:1707 ||| NNP
:  ||| S:1707 E:1709 ||| :
2.7 ||| S:1709 E:1712 ||| CD
,  ||| S:1712 E:1714 ||| ,
7.8  ||| S:1714 E:1718 ||| CD
mm ||| S:1718 E:1720 ||| NN
,  ||| S:1720 E:1722 ||| ,
P  ||| S:1722 E:1724 ||| NNP
< ||| S:1724 E:1726 ||| SYM
0.001 ||| S:1726 E:1731 ||| NNP
)  ||| S:1731 E:1733 ||| -RRB-
was  ||| S:1733 E:1737 ||| VBD
also  ||| S:1737 E:1742 ||| RB
observed  ||| S:1742 E:1751 ||| VBN
in  ||| S:1751 E:1754 ||| IN
benazepril  ||| S:1754 E:1765 ||| JJ
group ||| S:1765 E:1770 ||| NN
.  ||| S:1770 E:1772 ||| .
As  ||| S:1772 E:1775 ||| IN
the  ||| S:1775 E:1779 ||| DT
most  ||| S:1779 E:1784 ||| RBS
common  ||| S:1784 E:1791 ||| JJ
side  ||| S:1791 E:1796 ||| NN
effect  ||| S:1796 E:1803 ||| NN
after  ||| S:1803 E:1809 ||| IN
benazepril  ||| S:1809 E:1820 ||| JJ
treatment ||| S:1820 E:1829 ||| NN
,  ||| S:1829 E:1831 ||| ,
cough  ||| S:1831 E:1837 ||| NN
had  ||| S:1837 E:1841 ||| VBD
a  ||| S:1841 E:1843 ||| DT
prevalence  ||| S:1843 E:1854 ||| NN
of  ||| S:1854 E:1857 ||| IN
11.6 ||| S:1857 E:1861 ||| CD
% ||| S:1861 E:1862 ||| NN
.  ||| S:1862 E:1864 ||| .
Other  ||| S:1864 E:1870 ||| JJ
side  ||| S:1870 E:1875 ||| NN
effects  ||| S:1875 E:1883 ||| NNS
were  ||| S:1883 E:1888 ||| VBD
rare ||| S:1888 E:1892 ||| JJ
.  ||| S:1892 E:1894 ||| .
Benazepril  ||| S:1894 E:1905 ||| NNP
is  ||| S:1905 E:1908 ||| VBZ
both  ||| S:1908 E:1913 ||| DT
efficacious  ||| S:1913 E:1925 ||| NN
and  ||| S:1925 E:1929 ||| CC
safe  ||| S:1929 E:1934 ||| JJ
in  ||| S:1934 E:1937 ||| IN
the  ||| S:1937 E:1941 ||| DT
management  ||| S:1941 E:1952 ||| NN
of  ||| S:1952 E:1955 ||| IN
Chinese  ||| S:1955 E:1963 ||| JJ
patients  ||| S:1963 E:1972 ||| NNS
with  ||| S:1972 E:1977 ||| IN
chronic  ||| S:1977 E:1985 ||| JJ
heart  ||| S:1985 E:1991 ||| NN
failure ||| S:1991 E:1998 ||| NN
.  ||| S:1998 E:2000 ||| .
